ClinicalTrials.Veeva

Find clinical trials for Non-Small-Cell Lung Cancer in Atlanta, GA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Triple Negative Breast Cancer

Non-Small-Cell Lung Cancer trials near Atlanta, GA, USA:

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

3-1402 will be evaluated in participants with metastatic or unresectable NSCLC with EGFR activating mutation or squamous or non-squamous NSC...

Active, not recruiting
Non-Small Cell Lung Cancer (NSCLC)
Drug: U3-1402 (FL-DP)
Drug: U3-1402 (CTM-1 Lyo-DP)

Phase 1

Daiichi Sankyo
Daiichi Sankyo

Atlanta, Georgia, United States and 19 other locations

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo

Dunwoody, Georgia, United States and 122 other locations

A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: MEDI4736

Phase 2

AstraZeneca
AstraZeneca

Lawrenceville, Georgia, United States and 137 other locations

This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in-...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: encorafenib
Drug: binimetinib

Phase 2

Pfizer
Pfizer

Atlanta, Georgia, United States and 158 other locations

of AZD9291 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor in patients with locally advanced or Metastatic Non...

Active, not recruiting
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Drug: Erlotinib 150/100 mg
Drug: Placebo Erlotinib 150/100mg

Phase 3

AstraZeneca
AstraZeneca

Atlanta, Georgia, United States and 168 other locations

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously...

Active, not recruiting
Advanced Non Small Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer
Drug: Docetaxel
Drug: MRTX849

Phase 3

Mirati Therapeutics
Mirati Therapeutics

Marietta, Georgia, United States and 227 other locations

and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non...

Active, not recruiting
Non Small Cell Lung Cancer (Stage III)
Drug: Osimertinib 80mg/40mg
Drug: Placebo Osimertinib 80mg/40mg

Phase 3

AstraZeneca
AstraZeneca

Atlanta, Georgia, United States and 117 other locations

, early-stage non-small cell lung cancer....

Enrolling
Non-small Cell Lung Cancer
Drug: Cisplatin
Drug: Oleclumab

Phase 2

AstraZeneca
AstraZeneca

Gainesville, Georgia, United States and 94 other locations

This pilot trial studies the side effects of giving pembrolizumab together with stereotactic radiosurgery to treat patients with melanoma or non...

Active, not recruiting
Stage IV Non-Small Cell Lung Cancer
Mucosal Melanoma
Biological: Pembrolizumab
Radiation: Stereotactic Radiosurgery

Phase 1

Emory University
Emory University

Atlanta, Georgia, United States

The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patient...

Active, not recruiting
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Other: Best Standard of Care
Device: NovoTTF-200M device

Phase 3

NovoCure
NovoCure

Atlanta, Georgia, United States and 127 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems